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BCA  Bicinchoninic acid
BSA  Bovine serum albumin
CHO  Chinese hamster ovary
EDC  1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide
GST  Glutathione S-transferase
HEPES  2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesul-
fonic acid
HBS  HEPES buffered saline
IPTG  Isopropyl-β-d-1-thiogalactopyranoside
LDL  Low density lipoprotein
LOX  Lectin-like oxidized low density lipoprotein 
(LDL) receptor
malBSA  Maleylated bovine serum albumin
NHS  N-hydroxysuccinimide
PBS  Phosphate buffered saline
POD  Peroxidase
PPAR  Peroxisome proliferator-activated receptor
RAGE  Receptor for advanced glycation endproducts
SDS  Sodium dodecyl sulfate
SPR  Surface plasmon resonance
Introduction
S100A12 is a member of the S100 protein family compris-
ing more than 20 calcium-binding proteins of the EF-hand 
Abstract The EF-hand type calcium-binding protein 
S100A12 exerts numerous intra- and extracellular functions 
of (patho)physiological relevance. Therefore, receptors of 
S100A12 are of high interest for research and clinical appli-
cations. Beside the extensively studied receptor for advanced 
glycation endproducts (RAGE), G-protein coupled recep-
tors and more recently, scavenger receptors are suggested 
to be putative S100A12 receptors. Own findings and further 
information from the literature predestined CD36, a class B 
scavenger receptor, as promising candidate. To substantiate or 
prove against this hypothesis, this study aimed at investiga-
tion of interaction of S100A12 and CD36 on molecular and 
cellular level by the use of surface plasmon resonance (SPR), 
radio- and fluorescence-tracer-based cell binding, and cell 
activation experiments. S100A12 revealed binding affinity to 
CD36 in the low nanomolar range, essentially, at the CD36 
thrombospondin-1 binding site. Additionally, S100A12-medi-
ated translocation of CD36 to the membrane and elevation of 
both CD36 and peroxisome proliferator-activated receptor γ 
(PPARγ) expression was observed, which suggest a potential 
regulatory function of S100A12–CD36 interaction.
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type. Most of them are small (molecular weight <13 kDa) 
distinctly homoacidic proteins (Donato et al. 2013), which 
regulate numerous intracellular and/or extracellular func-
tions, including activation of enzymes, maintenance of 
calcium homeostasis, interaction with cytoskeletal com-
ponents, and interaction with receptors (Vogl et al. 1999; 
Hatakeyama et al. 2004; Donato et al. 2013). Once released 
into the extracellular space or the circulating blood, 
mostly by granulocytes, S100A12 in a cytokine-like man-
ner exerts proinflammatory effects, e.g., in lymphocytes, 
macrophages, mast cells, endothelial cells, and neurons 
(Mikkelsen et al. 2001; Yang et al. 2001, 2007; Pietzsch 
and Hoppmann 2009). Consequently, dysregulation in 
S100A12 secretion is found in many pathological situations 
like atherosclerosis, diabetes, chronic inflammatory disor-
ders, and cancer (Kosaki et al. 2004; Salama et al. 2008; 
Mori et al. 2009; Pietzsch and Hoppmann 2009; Donato 
et al. 2013). The most extensively studied interaction part-
ner of extracellular S100A12 is the proinflammatory recep-
tor for advanced glycation endproducts (RAGE) (Hofmann 
et al. 1999; Leclerc et al. 2009; Hoppmann et al. 2010). 
In vitro findings in mast cells that did not show RAGE 
synthesis provided evidence on putative G-protein coupled 
S100 receptors (Yan et al. 2008). Moreover, in vitro experi-
ments with endothelial cells and macrophages and in vivo 
experiments in rats using 18F-radiolabeled S100A12 pro-
vided first evidence that S100A12 also binds to scavenger 
receptors as demonstrated by us (Hoppmann et al. 2010). In 
this former study, scavenger receptor binding of S100A12 
could be substantially blocked by maleylated bovine serum 
albumin (malBSA), a pan-scavenger receptor ligand, but 
not by polyinosinic acid and fucoidan, two class A scav-
enger receptor ligands (Acton et al. 1994; Platt et al. 1996; 
Fyrnys et al. 1997; Hsu et al. 2001; Thelen et al. 2010; 
Hoppmann et al. 2010; Yu et al. 2012). Of importance, 
malBSA binds to scavenger receptors of class A (SR-A1, 
SR-A2), class B (CD36), and the lectin-like oxidized low 
density lipoprotein (LDL) receptor-1 (LOX-1) (Sawamura 
et al. 2000; Mehta and Li 2002). This finding and further 
information from the literature predestined CD36 to be a 
strong candidate as S100A12-recognizing receptor of the 
scavenger receptor family. CD36 is a membrane receptor 
that is present on platelets, macrophages, monocytes, adi-
pocytes, hepatocytes, myocytes, and some epithelial cells 
(Silverstein and Febbraio 2009). In monocytes and mac-
rophages, CD36 acts as receptor and transporter for bioac-
tive lipids leading to the activation of the peroxisome pro-
liferator-activated receptor γ (PPARγ) signaling pathway, 
which subsequently regulates glucose metabolism and free 
fatty acid uptake (Tontonoz et al. 1998; Koonen et al. 2005; 
Graessler et al. 2007). It has to be considered that RAGE 
and certain scavenger receptors share a common ligand 
recognition principle based on electrostatic interactions 
between the positively charged receptor surface domains 
and negatively charged ligands (Adachi and Tsujimoto 
2006; Jimenez-Dalmaroni et al. 2009; Gao et al. 2010; Fritz 
2011). In this regard, there is an experimental evidence that 
well-characterized RAGE-ligands, such as advanced gly-
cation endproducts, hypochlorite-modified proteins/apoli-
poproteins, and amyloid-β, also bind to CD36 (Ohgami 
et al. 2001; Kopprasch et al. 2004; Marsche et al. 2007; 
Jones et al. 2013). Another important property RAGE and 
CD36 have in common is the activation of signaling cas-
cades (Goyette et al. 2009; Park 2014). This distinguishes 
CD36 from other scavenger receptors, e.g., those of class 
A. Additionally, S100A12 and CD36 are expressed in simi-
lar cell types, and more interestingly, the dysregulation of 
S100A12 and CD36 is related to similar pathological out-
comes like atherosclerosis (Goyette et al. 2009; Park 2014).
To check the hypothesis that CD36 is a putative 
S100A12 receptor, this study aimed to investigate the pos-
sible interaction of S100A12 and CD36 on molecular and 
cellular level by the use of surface plasmon resonance 
(SPR), cell association and cell activation experiments.
Methods
Cell lines
Chinese hamster ovary (CHO)-K1 and CHO-CD36 cells 
were purchased from ATCC. CHO-RAGE cells were gen-
erated as described elsewhere (Hoppmann et al. 2010). 
Briefly, the vector pDNR-LIB-flRAGE was cloned into the 
eukaryotic expression vector pIRES-AcGFP1. For ampli-
fication, the vector was transfected into E. coli Top10 and 
positive clones were selected using 50 µg/mL kanamycin. 
Positive clones were checked for success of cloning and 
transfection using colony-PCR and sequencing analy-
ses (Agowa GmbH). Transfection of plasmid-DNA into 
CHO-cells was performed using Lipofectamine™ 2000. 
Transfection was performed in serum free medium with 
1 µg of plasmid-DNA and for 6–8 h at 37 °C under normal 
cell culture conditions (5 % CO2, v/v). Subsequently, cells 
were incubated in serum containing medium with selected 
antibiotics (300 µg/mL G418 and 250 µg/mL Zeocin). The 
success of transfection of CHO-RAGE cells was checked 
using fluorescence microscopy, Western blot analyses and 
flow cytometry.
Immunocytochemical analysis
Synthesis of CD36 and RAGE was detected by immuno-
cytochemical staining. Therefore, cells were fixed with 
4 % (w/v) paraformaldehyde and 2.5 % (w/v) sucrose in 
phosphate buffered saline (PBS). After permeabilization 
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with 0.3 % (v/v) Triton-X-100 in PBS, unspecific binding 
sites were blocked with a blocking solution containing 5 % 
(w/v) bovine serum albumin (BSA) and 0.5 % (v/v) Tween 
20 in PBS. For antibody staining, the monoclonal anti-
CD36 antibody [FA6-152] (abcam17044, 1:50) and the 
polyclonal anti-RAGE antibody (R&D systems, AF-1145 
1:50) as well as secondary antibodies, anti-mouse Alex-
aFluor488® (for anti-CD36 antibody) and anti-goat Alex-
aFluor594® (for anti-RAGE antibody) were used. Counter-
staining was conducted using the cell DNA marker Hoechst 
33258 (5 µg/mL). Images were acquired using the confocal 
laser-scanning microscope IX83 (Olympus).
Western blot analysis
Western blot analyses were performed as published else-
where (Wolf et al. 2011). In short, sodium dodecyl sulfate–
polyacrylamide electrophoresis of cell lysates with follow-
ing semidry Western blotting was performed. Blots were 
blocked using blocking solution containing 5 % (w/v) dry 
milk powder, 2 % (w/v) BSA and 0.05 % (v/v) Tween 20 
in Tris-buffered saline. For antibody staining, the monoclo-
nal anti-CD36 antibody [FA6-152] (abcam17044, 1:500) 
and the polyclonal anti-RAGE antibody (R&D systems, 
AF-1145 1:500) as well as the peroxidase (POD) coupled 
secondary antibodies (anti-mouse IgG-POD for anti-CD36 
antibody and anti-goat IgG-POD for anti-RAGE antibody) 
were used. Images were acquired using the Super Signal 
Dura and Pico kit (Thermo Scientific). Western blots were 
obtained from two experimental settings: (a) lysates were 
obtained from cells grown in cell culture medium supple-
mented with 10 % fetal calf serum, (b) for cell activation 
studies lysates were obtained from cells after incubation 
for 90 min with serum-free calcium binding buffer (20 mM 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES), 150 mM NaCl, 1.2 mM MgCl2, 1.3 mM CaCl2; 
pH 7.5).
Recombinant S100A12 synthesis
Recombinant expression and purification of S100A12 
(rS100A12) was performed as published elsewhere (Hopp-
mann et al. 2008). Briefly, pGEX-S100A12 transformed 
E.coli BL21 was cultivated in LB medium supplemented 
with 50 µg/mL ampicillin at 37 °C with shaking. When 
optical density (600 nm) of 1.0 was reached, protein 
expression was induced by adding 0.5 mmol/L isopropyl-
β-d-1-thiogalactopyranoside (IPTG) for 4 h at 25 °C. 
The cell pellet was lysed using 20 % (v/v) Triton X-100, 
4000 U/mL lysozyme, 25 U/mL benzonase and ultra-
sound. RS100A12 protein was purified using glutathione-
sepharose. Glutathione S-transferase (GST) free proteins 
were eluted using PreScission™ protease (GE Healthcare). 
Further purification was performed using size exclusion 
chromatography. The purified protein was analyzed by 
mass spectrometry and Western blot (polyclonal goat anti-
hEN-RAGE/S100A12, R&D Systems, AF1052). After snap 
freezing in liquid nitrogen, the purified protein was stored 
at -65 °C until usage for further experiments. Furthermore, 
commercially available native human S100A12 protein 
(nS100A12) was obtained from Life Technologies with the 
reference number 11143-HNAE-50. Compared to the pur-
chased native nS100A12 the recombinant synthesized pro-
tein rS100A12 possesses five additional N-terminal amino 
acids (GPLGS) (Hoppmann et al. 2008).
Fluorescence‑ and radiolabeling of recombinant 
rS100A12
Radiolabeling of rS100A12 with N-succinimidyl 4-[18F]
fluorobenzoate ([18F]SFB) was performed as published 
by us earlier for the investigation of the interaction of 
S100A12 and RAGE (Hoppmann et al. 2008, 2010). 
Briefly, [18F]SFB diluted in acetonitrile was directly added 
to the rS100A12 solution in PBS and incubated for 30 min 
at 37 °C. The radiolabeled 4-[18F]fluorobenzoyl-([18F]FB)-
rS100A12 was purified using a HiTrap desalting column 
(GE Healthcare) with the ÄKTAprime® plus (GE Health-
care) chromatography system. The activity of the product 
was determined using the ISOMED 2000 calibrator (Nuk-
lear-Medizintechnik Dresden GmbH).
To obtain a second, labeled S100A12 protein species, as 
independent marker for cell binding experiments and SPR 
studies (as described below), fluorescein-labeled rS100A12 
was synthesized. Therefore, N-hydroxysuccinimide-fluo-
rescein [(NHS)-fluorescein, Thermo Scientific] was used 
by following the manufacturer’s instruction. Briefly, 1 mg 
of rS100A12, (M = 10,974 g/mol, c = 1 mg/mL) in borate 
buffer (pH 8.0) was reacted with 15 times molar excess of 
NHS-fluorescein (M = 473.4 g/mol, c = 10 mg/mL) for 
1 h at room temperature. Purification of the fluorescein-
rS100A12 was performed in Slide-A-Lyzer™ dialysis cas-
settes (Thermo Fisher) with an exclusion size of M < 7000 g/
mol. Depending on the following study PBS or calcium 
binding buffer (20 mM 2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid (HEPES), 150 mM NaCl, 1.2 mM 
MgCl2, 1.3 mM CaCl2; pH 7.5) were used.
Cell binding experiments
To quantify the amount of [18F]FB-rS100A12 binding 
cells were incubated with [18F]FB-rS100A12 in PBS++ 
for 90 min at 37 °C. For blocking, a 15-fold excess of 
rS100A12 related to [18F]FB-rS100A12 or the monoclo-
nal anti-CD36 antibody (FA6-152, abcam, c = 10 mg/
mL) (Olivetta et al. 2014; Wang et al. 2014) was added to 
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the cells 20 min at room temperature before starting the 
binding experiment. After incubation cells were lysed with 
NaOH (0.1 M) and sodium dodecyl sulfate (SDS) [1 % 
(w/v)]. Activity was quantified using the gamma counter 
COBRA™ II. Obtained activity values were put in rela-
tion to the starting activity (% ID) and the amount of pro-
tein in the cell lysate. Protein determination was performed 
using the Pierce® bicinchoninic acid (BCA) Protein Assay 
(Thermo Scientific) following the manufacturer’s instruc-
tion. The amount of cellular fluorescein-rS100A12 binding 
was determined similar to the [18F]FB-rS100A12 experi-
ments. Cells were grown in 24-well plates to 80 % conflu-
ence. Cells were incubated with 200 µL of incubation solu-
tion for 90 min at 37 °C. For antibody blocking experiments, 
the monoclonal anti-CD36 antibody (FA6-152, abcam) was 
added to the cells for 30 min at 37 °C in a concentration of 
10 µg/mL before starting the cell binding experiment. After-
wards, cells were lysed with sodium hydroxide (NaOH, 
0.1 M) and SDS [1 % (w/v)]. Fluorescence signal quanti-
fication was checked with assays using cell lysates using 
the Synergy™ 4 Multi-Mode Microplate Reader (BioTek) 
with λEx = 485 nm, λEm = 525 nm as filter setting. Obtained 
relative fluorescence units were put in relation to the amount 
of protein in the cell lysate. Protein determination was per-
formed using the Pierce® BCA Protein Assay (Thermo Sci-
entific) following the manufacturer’s instruction.
Surface plasmon resonance
The SPR analyses were performed using a Biacore T100 
(GE Healthcare). The ligand, CD36 (His-tagged recom-
binant human protein, Sino Biological, Life technologies, 
70-80 kDa), was immobilized on a C1 sensor chip using 
the amine coupling kit (GE Healthcare) and PBS (GE 
Healthcare). The employed C1 amine coupling proce-
dure comprises a surface cleaning step using a solution of 
0.03 % (v/v) Triton T100 in 100 mM glycine (pH 12.3), the 
surface activation by 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC)/NHS, the coupling step using a solu-
tion of CD36 at a concentration of 20 µg/mL in 10 mM 
acetate buffer (pH 4), and the blocking of the surface using 
ethanolamine. Afterwards 1000 RU of CD36 was immobi-
lized on the sensor surface. A reference cell was prepared 
by blank immobilization. 350 µM CaCl2 in HEPES buff-
ered saline (HBS)-P + buffer (GE Healthcare) was sterile 
filtered and used for further SPR experiments. Kinetic data 
were obtained by a single cycle kinetic using the respective 
S100A12 species rS100A12 and nS100A12 in concentra-
tions of 0.62, 1.85, 5.56, 16.67, and 50.0 nM. The analyte 
was injected over the two flow cells at a flow rate of 30 µL/
min and at a temperature of 25 °C. The association and dis-
sociation time was 90 and 900 s, respectively. The surfaces 
were regenerated by a sequence of glycine (10 mM, pH 
1.5, 5 s) and NaOH (0.05 mM, 5 s) followed by a stabiliza-
tion period of 300 s. Starting from the respective solution 
of r/nS100A12, six 50 nM stock solutions were prepared 
which were further diluted in triplicate to yield the given 
final concentrations of the analyte. A buffer blank run was 
performed at the beginning and the end of each sequence 
comprising nine single cycle kinetics with r/nS100A12. 
Data were collected at a rate of 10 Hz. The data were fitted 
to a two-state reaction model including reference subtrac-
tion and blank buffer correction derived from both blank 
runs using the Biacore Evaluation software 2.0.4.
Cell activation experiments
Cells were grown in 100 mm petri dishes or chamber 
slides to 80 % confluence. After short washing with PBS, 
cells were incubated with 2 % (w/v) BSA in calcium bind-
ing buffer for 1 h at 37 °C. Afterwards, incubation with 
5 µM endotoxin free rS100A12 in calcium binding buffer 
or with calcium binding buffer alone, as negative control, 
was performed for 90 min at 37 °C. Cells were lysed for 
Western blot analysis or fixed using 4 % (w/v) paraform-
aldehyde for immunocytochemical staining. Western blot 
analysis of PPARγ synthesis was performed using a mon-
oclonal antibody (abcam191407). Additionally, Western 
blot analyses of tyrosine kinases Fyn (#4023, cell signal-
ling), pFyn (ab53690, abcam), Lyn (#2796, cell signalling), 
pLyn (ab33914, abcam) and mitogen-activated kinase p38 
(ab4822, abcam) were performed.
Statistical analysis
Statistical significance of all cell-binding experiments and 
SPR experiments was calculated using a one-way ANOVA 
followed by a Bonferroni post hoc test for the column anal-
ysis with Prism6 (GraphPad Software). Statistical signifi-
cance was assumed for p < 0.05 and p < 0.01.
Results
CHO cell lines expressing CD36 and RAGE
Immunocytochemistry (Fig. 1a) and Western blot analyses 
(Figs. 1b, S1a) revealed the specific synthesis of the two 
receptors of interest by the different CHO cell lines. CHO-
K1 showed no synthesis of RAGE in Western blot and 
immunocytochemistry. A very low synthesis of CD36 could 
be observed for the CHO-K1 cells. The CD36 synthesis 
could also be observed in an even smaller amount for the 
CHO-RAGE cells. On the other hand, the CHO-CD36 cell 
lines showed very high synthesis of CD36 in immunocy-
tochemical images and with Western blot. Immunostaining 
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for RAGE revealed that only the CHO-RAGE cell line 
showed synthesis of RAGE.
Cell binding experiments
In Fig. 2a the cell binding of [18F]FB-rS100A12 to the 
CHO cell lines at 37 °C is shown. Compared to CHO-K1 
cells, cell association of [18F]FB-rS100A12 was signifi-
cantly higher by 40 % in CHO-RAGE cells and by 20 % 
in CHO-CD36 cells. On the other hand, using the CD36-
specific antibody (FA6-152) binding of [18F]FB-S100A12 
to CHO-CD36 cells could be substantially blocked. There-
fore, a specific binding of [18F]FB-S100A12 to CD36 could 
be confirmed. The fact that [18F]FB-rS100A12 was blocked 
by unlabeled rS100A12 indicates a similar binding behav-
ior of both the unlabeled and the labeled species.
As independent marker for cell binding fluorescein 
labeled S100A12 was used. Therefore, experiments were 
performed with 10 µM of fluorescein-S100A12. Compared 
to CHO-K1 cells, binding was significantly higher by 50 % 
in CHO-RAGE and by 30 % in CHO-CD36 cells (Fig. 2b). 
Using a specific monoclonal blocking antibody (FA6-152) 
against CD36, binding to CHO-CD36 cells was reduced by 
40 % compared to the non-blocked situation which indi-
cates the specificity of the interaction.
SPR analyses
SPR analyses were performed to characterize binding 
of S100A12 to CD36 at the protein–protein interaction 
level. Human recombinant CD36 (Life Technologies, ref-
erence number 10752-H08H-50, His Tag, active) was 
chosen as ligand and immobilized on the sensor surface 
by EDC/NHS amine coupling chemistry. A blank immo-
bilized sensor surface served as reference cell to account 
for non-specific binding effects. Recombinant rS100A12, 
commercially available human, untagged recombinant 
nS100A12, and fluorescein-labeled rS100A12 were used 
as ligands. Experiments were performed as single cycle 
kinetics and analytes were used in a concentration range 
of 0.62–50.0 nM (Fig. 3a). KD values were determined by 
fitting the observed sensorgrams using a two-state reaction 
model. The rS100A12, nS100A12, and fluorescein-labeled 
rS100A12 showed binding to CD36 (Fig. 3a, b). The affini-
ties of rS100A12 (batch #1: KD = 0.67 ± 0.17 nM; batch 
#2: KD = 0.99 ± 0.33 nM) and commercially available 
nS100A12 (batch #1: KD = 1.04 ± 0.50 nM; batch #2: 
KD = 0.90 ± 0.22 nM) to CD36 did not differ significantly 
and were determined to be close to 1 nM. In comparison, 
fluorescein-labeled rS100A12 showed a weaker binding 
affinity (KD = 4.79 ± 0.38 nM) to CD36.
Fig. 1  CD36 and RAGE 
expression. a Immunocyto-
chemistry of CHO-K1, CHO-
CD36 and CHO-RAGE cells 
using anti-CD36 (green) and 
anti-RAGE (red) specific anti-
bodies. b Western blot analyses 
of CHO-K1, CHO-CD36 and 
CHO-RAGE cell lysates using 
anti-CD36 and anti-RAGE 
specific antibodies
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Cell activation experiments
Although S100A12 showed high affinity to CD36, acti-
vation of proteins that interact directly with CD36 or are 
activated by the CD36 signaling cascade (Fyn, pFyn, Lyn, 
pLyn, p38) could not be observed in CHO-K1, CHO-CD36, 
and CHO-RAGE cells by immunoblotting (Fig. S2a–e). 
However, incubation of CD36-positive CHO cells with 
rS100A12 lead to the recruitment of CD36, which nor-
mally is diffusely distributed in vesicles, to the cell surface 
(Fig. 4a, b). On the other hand, the incubation of CHO-K1, 
CHO-CD36, and CHO-RAGE cells with rS100A12 lead 
to an increased synthesis of CD36 itself (Figs. 4c, S1b). 
This can be seen especially in CHO-K1 and CHO-RAGE 
cell lines that have low expression of CD36 under baseline 
conditions as already described above. Additionally, an up-
regulation of the PPARγ synthesis of all cell lines could be 
observed in preliminary studies (Fig. 4d). Therefore, poten-
tial regulatory mechanisms based on binding of S100A12 
to CD36, and subsequently, leading to both higher recruit-
ment of CD36 to the cell membranes and an elevation of 
CD36 synthesis could be hypothesized.
Fig. 2  Cell binding of labeled 
rS100A12. Cell binding experi-
ments with a [18F]FB-rS100A12 
and b fluorescein-labeled 
rS100A12 were performed at 
37 °C in CHO-K1 cells, CHO-
CD36 cells, CHO-CD36 cells 
blocked with anti-CD36 anti-
body (and in case of a excess 
of unlabeled rS100A12), and 
CHO-RAGE cells. (n = 6–12, 
*<0.05, **p < 0.01)
Fig. 3  In vitro binding of S100A12 proteins to immobilized CD36. 
Surface plasmon resonance binding experiments of a rS100A12 (left), 
nS100A12 (middle), and fluorescein-labeled rS100A12 (right) to 
CD36 were performed. Results of representative experiments (sub-
tracted sensorgrams) are shown. For evaluation of S100A12 binding 
kinetics, single-cycle kinetics was performed using concentrations 
ranging from 0.62 to 50.0 nM (1–0.62, 2–1.85, 3–5.56, 4–16.67, 
5–50 nM). Solid lines represent observed data; dotted lines indicate 
computer-derived fits as calculated by a two-state reaction model. In 
b the calculated ka, kd, and, KD values are shown. (n = 8–19)
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Discussion
For the investigation of potential S100A12–CD36 binding, 
CHO cell lines were used. Immunoblotting and immunocy-
tochemical analyses revealed that the CHO-K1 cell line is a 
good negative control exhibiting no synthesis of RAGE and 
only low synthesis CD36. On the other hand, CHO-CD36 
cells and CHO-RAGE cells show a high synthesis of CD36 
and RAGE, respectively, without or with low synthesis of 
the respective other receptor. This study substantiates our 
former hypothesis on binding of S100A12 to members 
of the scavenger receptor family (Hoppmann et al. 2010) 
and first demonstrated class B scavenger receptor CD36 
involved in high-affinity binding of S100A12. Cell binding 
experiments using both [18F] fluorobenzoylated and fluo-
rescein-labeled rS100A12 showed that S100A12 specifi-
cally binds to cells expressing CD36. Similarly, although in 
a higher amount, [18F]FB-rS100A12 binds to cells express-
ing RAGE, a well-characterized receptor of S100A12. 
Blocking with a CD36-specific monoclonal antibody 
[FA6-152] that specifically blocks the collagen and throm-
bospondin binding sites of CD36 (Doebele et al. 2009), 
revealed that S100A12 most likely shares the same bind-
ing site as thrombospondin or collagen and that the binding 
is specific (Silverstein and Febbraio 2009). Importantly, it 
has been described that this binding site is not identical to 
the fatty acid binding site of CD36, which is important for 
its function as fatty acid transporter (Silverstein and Feb-
braio 2009). The in vitro cell binding experiments were 
confirmed by SPR analyses. The latter revealed subna-
nomolar to low nanomolar binding affinities for unlabeled 
r/nS100A12 and fluorescein-labeled rS100A12 to CD36.
Interestingly, the incubation of the different CHO cells 
with rS100A12 led to the recruitment of CD36 to the cell 
membranes. CD36 membrane recruitment is known to be 
regulated also by other stimuli like insulin (Samovski et al. 
2012). Incubation of the CHO cells with S100A12 also 
leads to an increase of CD36 synthesis. This effect is even 
more striking looking at the less CD36 expressing cells 
like CHO-K1 and CHO-RAGE. Even though this effect 
Fig. 4  rS100A12 stimulated 
CD36 translocation, CD36 
expression, and PPARγ expres-
sion. Immunohistochemical 
staining of CHO-CD36 cells 
for CD36 (red) a before and 
b after incubation with 5 µM 
of rS100A12, cell nuclei are 
stained with Hoechst 33258 
(blue). Representative Western 
blot analysis of c CD36 syn-
thesis (n = 5) and preliminary 
Western blot analysis of d 
PPARγ synthesis of CHO-K1, 
CHO-CD36, and CHO-RAGE 
cells without (−) and after 
activation (+) with 5 µM of 
rS100A12 in calcium binding 
buffer for 90 min
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could be due to the autoregulation of CD36 it could also 
be caused by the binding of S100A12 to RAGE (Xanthis 
et al. 2009). This would explain the high up-regulation of 
CD36 in CHO-RAGE cells but not for the RAGE-negative 
CHO-K1 and CHO-CD36 cells. This finding leads to the 
presumption that S100A12 could activate PPARγ through 
increased import of bioactive lipids (Ahmadian et al. 2013) 
through a not completely understood pathway (Silverstein 
2009), which is consecutively increased by the membrane 
recruitment and the increase of CD36 synthesis (Tontonoz 
et al. 1998). The activation of PPARγ could also be seen in 
the higher protein synthesis of the protein itself.
Our results confirm that S100A12 shares the same binding 
site on CD36 as thrombospondin-1/-2 and collagen between 
amino acids 93 and 120 of CD36 (Doebele et al. 2009; Silver-
stein and Febbraio 2009). Oxidized LDL, on the other hand, 
has another binding site at the CD36 protein (Silverstein and 
Febbraio 2009). This is likely to support the hypothesis that 
the observed interaction of S100A12 and CD36, the subse-
quent recruitment of CD36 to the membrane, and the up-
regulation in CD36 synthesis, could be involved in transloca-
tion of fatty acids and regulation of PPARγ (Kopprasch et al. 
2004; Graessler et al. 2007; Silverstein and Febbraio 2009). 
But to prove this hypothesis, further investigations have to 
be carried out. Another hypothesis that could be deduced 
from our data will attribute participation of CD36 in forming 
clusters of various pattern recognition receptors, including 
RAGE and/or Toll-like receptors (Drage et al. 2009; Jime-
nez-Dalmaroni et al. 2009; Xanthis et al. 2009; Jones et al. 
2013). Here, CD36 could contribute exclusively to high-affin-
ity binding of S10012 without activation of CD36-specific 
downstream signaling, but activation of signaling pathways 
downstream the suspected individual co-receptors. A future 
challenge will be the experimental differentiation of the con-
ceivable, often highly redundant pathways (Lin 2006).
Concluding remarks
Taken together this study revealed S100A12 as potent bind-
ing partner of the class-B scavenger receptor/fatty acid 
translocase CD36. Binding could be observed by cell asso-
ciation experiments of labeled S100A12. SPR confirmed 
the binding revealing affinities in the low nanomolar range. 
A recruitment of CD36 to the surface of the CHO-CD36 
cells could be observed, which suggest a regulatory func-
tion of S100A12 for the lipid transport by direct interaction 
with CD36.
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